



572

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|---|--|---|--|
| (51) International Patent Classification ⁶ : A61K 49/00 | | A1 | (11) International Publication Number: WO 99/08714 (43) International Publication Date: 25 February 1999 (25.02.99) |
| <p>(21) International Application Number: PCT/GB98/02481</p> <p>(22) International Filing Date: 19 August 1998 (19.08.98)</p> <p>(30) Priority Data: 9717588.9 19 August 1997 (19.08.97) GB</p> <p>(71) Applicant (for GB only): MARSDEN, John, Christopher [GB/GB]; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).</p> <p>(71) Applicant (for all designated States except US): NYCOMED IMAGING AS [NO/NO]; Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo 4 (NO).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): ØSTENSEN, Jonny [NO/NO]; Nycomed Imaging AS, Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo 4 (NO). ERIKSEN, Morten [NO/NO]; Nycomed Imaging AS, Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo 4 (NO). TORNES, Audun [NO/NO]; Nycomed Imaging AS, Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo 4 (NO). FRIGSTAD, Sigmund [NO/NO]; Frode Rinnans Vei 68, N-7035 Trondheim (NO).</p> | | <p>(74) Agents: MARSDEN, John, Christopher et al.; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> | |
| <p>(54) Title: IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS</p> <p>(57) Abstract</p> <p>Ultrasound imaging using gas microbubble-containing contrast agents may be performed in the recirculating phase following admixture of the contrast agent with the blood pool, thereby prolonging the useful imaging time window compared to that conventionally obtained during the backscatter signal peak resulting from first pass of a contrast agent bolus. The length of the time window may further be increased by imaging at ultrasound frequencies of 2 MHz or less, particularly by harmonic imaging at transmit frequencies less than the resonance frequencies of the gas microbubbles.</p> | | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|---------------------------------------|----|---|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | NZ | New Zealand | | |
| CM | Cameroon | KR | Republic of Korea | PL | Poland | | |
| CN | China | KZ | Kazakhstan | PT | Portugal | | |
| CU | Cuba | LC | Saint Lucia | RO | Romania | | |
| CZ | Czech Republic | LI | Liechtenstein | RU | Russian Federation | | |
| DE | Germany | LK | Sri Lanka | SD | Sudan | | |
| DK | Denmark | LR | Liberia | SE | Sweden | | |
| EE | Estonia | | | SG | Singapore | | |

- 1 -

66964002.601

Improvements in or relating to contrast agents

5 This invention relates to gas-containing ultrasound contrast agents, more particularly to their use in diagnostic ultrasound imaging.

10 It is well known that ultrasonic imaging comprises a potentially valuable diagnostic tool, for example in studies of the vascular system, particularly in 15 cardiography, and of tissue microvasculature. A variety of contrast agents has been proposed to enhance the acoustic images so obtained, including suspensions of solid particles, emulsified liquid droplets, gas 20 microbubbles and encapsulated gases or liquids. It is generally accepted that low density contrast agents which are easily compressible are particularly efficient in terms of the acoustic backscatter they generate, and considerable interest has therefore been shown in the 25 preparation of gas-containing and gas-generating systems.

Initial studies involving free gas microbubbles generated *in vivo* by intracardiac injection of physiologically acceptable substances have demonstrated 25 the potential efficiency of such microbubbles as contrast agents in echography; such techniques are severely limited in practice, however, by the short lifetime of the free microbubbles. Substantial interest has accordingly been shown in methods of stabilising gas 30 bubbles for echocardiography and other ultrasonic studies, for example using emulsifiers, oils, thickeners or sugars, or by entraining or encapsulating the gas or a precursor therefor in a variety of systems, e.g. as porous gas-containing microparticles or as encapsulated 35 gas microbubbles, and in the selection of gases which may themselves exhibit enhanced stability and duration of echogenic effect.

Prior art concerning both the use of phospholipids

- 2 -

as components of gas-containing ultrasound contrast agents and the selection of gases said to give improved persistence *in vivo* is reviewed in WO-A-9729783, the contents of which are incorporated herein by reference.

5 WO-A-9729783 itself discloses contrast agents for use in diagnostic studies comprising a suspension in an injectable aqueous carrier liquid of gas microbubbles stabilised by phospholipid-containing amphiphilic material, characterised in that the amphiphilic material

10 consists essentially of phospholipid predominantly comprising molecules with net charges. The phospholipid molecules are preferably negatively charged, for example as in naturally occurring (e.g. soya bean or egg yolk derived), semisynthetic (e.g. partially or fully

15 hydrogenated) and synthetic phosphatidylserines, phosphatidylglycerols, phosphatidylinositols, phosphatidic acids and cardiolipins.

Contrast agents in which at least 70% of the phospholipid content consists of one or more phosphatidylserines, for example saturated (e.g. hydrogenated or synthetic) natural phosphatidylserine and synthetic or semi-synthetic dialkanoylphosphatidylserines such as distearoylphosphatidylserine, dipalmitoylphosphatidylserine and diarachidoyl-

25 phosphatidylserine, are said to be preferred by virtue of their stability, minimal haemodynamic side effects and ease of elimination from the body.

Gases which may be present in such contrast agents include any substances (including mixtures) substantially or completely in gaseous (including vapour) form at the normal human body temperature of 37°C. Representative gases thus include air, nitrogen, oxygen, carbon dioxide, hydrogen, nitrous oxide, inert gases, sulphur fluorides, hydrocarbons and halogenated hydrocarbons, especially fluorocarbons such as perfluorocarbons, typically containing 1-5 carbon atoms. The use of fluorinated gases such as sulphur hexafluoride, perfluoroalkanes and perfluorocycloalkanes

- 3 -

is particularly preferred.

Ultrasound contrast agents are usually administered intravenously as a single bolus dosage, leading to a rapid and pronounced but relatively short lasting rise
5 in backscatter intensity in respect of blood-perfused tissue and organs as the bolus mixes with surrounding blood, thereby generating a relatively narrow and high intensity backscatter signal peak in a plot against time; backscatter measurements are normally made during
10 the existence of this peak. This may, however, give rise to problems in, for example, the imaging of deeper tissues and organs, where high backscatter from overlying tissue during the peak period may cause excessive shadowing.

15 It is often desirable to prolong the useful time window for imaging beyond the relatively short duration of the backscatter signal peak resulting from passage of the contrast agent bolus. In the case of non-recirculating contrast agents, i.e. agents which are
20 incapable of surviving more than one passage through the systemic circulation, for example as a result of instability or of specific or non-specific trapping in certain tissues, this may require repeated injection or continuous infusion of the contrast agent; however, such
25 techniques may be inconvenient in practice and may require special pharmaceutical formulations. Use of increased dosages of non-recirculating contrast agents in an attempt to prolong the imaging time window may be limited by toxicity considerations and will frequently
30 cause excessive acoustic shadowing, thereby significantly shortening the useful time window.

Stabilised gas microbubble-containing contrast agents such as those disclosed in WO-A-9729783 are capable of surviving passage through the systemic circulation. Such agents can pass through the pulmonary capillary bed and survive the systolic pressure changes encountered in the blood stream, and so may provide measurable backscatter levels after mixture with the
35

- 4 -

whole blood pool. In such cases a plot of backscatter intensity against time will exhibit a decay phase after the peak period as a result of the presence of echogenic contrast agent in recirculating blood; this is
5 hereinafter referred to as the "recirculating phase". Hitherto, measurements of backscatter intensity during the recirculating phase have generally been disregarded, probably because of the low intensity levels involved. It has now surprisingly been found, however, that
10 imaging during the recirculating phase may provide diagnostically useful results over a prolonged time period if a sufficient dosage of contrast agent is administered.

Thus the present invention is based on the finding
15 that increasing the dose of a recirculating ultrasound contrast agent may lead to a substantial and disproportionately large increase in the useful imaging time window. Without wishing to be bound by theoretical considerations, it is thought that this unexpectedly
20 prolonged time window may be the result of a change in the mechanism governing contrast duration. Thus, at low doses, contrast duration is determined solely by the bolus transit time, which is governed by the relationship between central blood volume and cardiac
25 output. At high doses, on the other hand, contrast duration depends on clearance of the contrast agent from the blood, for example on the relationship between total blood volume and hepatic blood flow in the case of a contrast agent with predominantly hepatic clearance.

30 Thus according to one aspect of the invention there is provided a method of ultrasound imaging which comprises (i) administering an ultrasound contrast agent comprising a stabilised dispersion of gas microbubbles in an injectable carrier liquid to the vascular system
35 of a subject in an amount which is physiologically tolerable and sufficient to generate contrast enhancement within blood in a recirculating phase following admixture of the agent with the blood pool;

- 5 -

and (ii) generating an ultrasound image of at least a part of the vascular system of said subject during said recirculating phase.

In a further embodiment the invention provides use
5 of stabilised gas microbubbles in the manufacture of a contrast agent for administration to the vascular system of a subject in a dosage unit which is physiologically tolerable and sufficient to generate contrast enhancement within blood in a recirculating phase
10 following admixture of the agent with the blood pool.

The contrast agents may, for example, comprise amphiphile-stabilised, e.g. phospholipid-stabilised, gas microbubbles, advantageously in which the phospholipids or other amphiphiles form monolayer membranes at the
15 microbubble-carrier liquid interfaces; such agents may combine high efficacy and low toxicity by virtue of the flexibility and low material content of the stabilising membranes. The use of negatively charged phospholipids as described in WO-A-9729783 is preferred, the use of
20 phosphatidylserines, e.g. to stabilise fluorinated gases such as perfluorobutane, being particularly preferred since the particularly low toxicity of such products facilitates their use at higher dosages.

Such contrast agents may, for example, be
25 administered at up to 30, e.g. 5-15 times the dosage which might normally be employed for conventional imaging of tissue such as the myocardium during the peak concentration period. Thus in the case of harmonic imaging using contrast agents as described in WO-A-
30 9729783, contrast agent doses such that the amount of phospholipid injected is in the range 2-10 µg/kg may be useful. The agents may, for example, be administered as a plurality of small doses in sequence, as a continuous infusion over an appropriate period of time or as a
35 single high dose; this last method will generally be preferred for simplicity and convenience.

It will be appreciated that, for any given contrast agent, there will be an upper dosage limit above which

- 6 -

shadowing will dominate for a dosage-dependent period of time, whereafter the useful imaging time window will begin; the length of the time window will remain constant at any dosage above this upper limit. The optimum dosage will therefore be one which gives substantial prolongation of the time window without causing shadowing in the recirculating phase.

Whereas imaging during the peak concentration period is typically constrained to an imaging time window of at most 4 minutes, sometimes less than 1 minute, imaging in the recirculating phase in accordance with the present procedure of tissue such as the myocardium may give an imaging time window in excess of 10, 15, 30 or even 45 minutes.

The useful imaging time window effectively ends when the backscatter from contrast agent in the recirculating phase falls to the tissue baseline level. It is therefore advantageous to use harmonic imaging techniques such as second harmonic imaging in the method of the invention, since these suppress tissue echo relative to contrast echo and will therefore extend the imaging time window. Thus, for example, a relative suppression of tissue echo by 10 dB will prolong the effective imaging time by about 3 halftimes, since $0.1 = (0.5)^3$.

It has also been found that imaging time windows, particularly for deeply located tissue sites, may be lengthened by use of lower than usual ultrasound imaging frequencies. It is well known that increased ultrasound frequency leads to enhanced image resolution but also results in higher attenuation; it is accordingly necessary to compromise in order to balance the requirements of adequate resolution and tissue penetration. Current diagnostic ultrasound imaging procedures typically employ frequencies of 2-10 MHz for transcutaneous measurements; thus, for example, frequencies of 2.5-5 MHz, e.g. 3.5 MHz, are commonly employed in adult cardiology and deep organ imaging.

- 7 -

Where highly echogenic gas microbubble-containing contrast agents are used, imaging of deeply located tissue sites of interest may be hindered as a result of attenuation (and therefore shadowing) by contrast agent 5 in overlying tissue. Imaging of tissue in the region of interest will thus not be practicable until such attenuation has fallen sufficiently for backscatter from the tissue of interest to be determinable, thereby delaying onset of the time window for useful 10 observations. This time window will then last until backscatter from the tissue of interest falls below the minimum level for useful observations.

The use of lower imaging frequencies, e.g. 2 MHz or less, may lengthen the imaging time window by reducing 15 or even eliminating attenuation by contrast agent in overlying tissue and possibly also by such tissue itself, thereby advancing the time from which useful observations of the underlying tissue of interest may be made.

20 The imaging frequency may, for example, be in the range 1-2 MHz, and may advantageously be less than 1.8 MHz, preferably less than 1.6 MHz, for example about 1.5 MHz. The use of harmonic imaging techniques, for example second harmonic imaging, and analogous 25 techniques such as pulse inversion imaging, may be particularly advantageous; in such cases the above-defined frequencies refer to the transmitted ultrasound signals.

It will be appreciated that such transmit 30 frequencies are significantly below the resonance frequencies of most gas microbubble-containing contrast agents, these typically being of the order of 3-5 MHz. It has hitherto been a general belief that non-linear imaging techniques such as harmonic imaging require 35 oscillation of microbubbles at their resonance frequency (see, for example, Ultrasonics 15(1), pp. 7-13 (1977)), so that deviation from the resonance frequency is generally considered to be disadvantageous. The finding

- 8 -

that harmonic imaging at a transmit frequency below the resonance frequency of the microbubbles produces improved contrast to tissue signal ratios and thus substantially prolongs the useful imaging time window is
5 therefore most unexpected.

Without wishing to be bound by theoretical considerations, it is believed that non-linear imaging such as second harmonic imaging does not in fact require the phenomenon of microbubble resonance. Thus, provided
10 that a sufficient oscillation amplitude is experienced at the transmit frequency, non-linear oscillations may be the main source of harmonic components in the contrast obtained from contrast agent microbubbles, although not at the optimum level corresponding to
15 resonance frequencies.

The use of lower transmit frequencies is advantageous in that attenuation is thereby reduced, allowing more power to penetrate and reach the region of interest and so giving more efficient harmonic
20 conversion. Since, as noted above, shadowing is reduced by the use of lower frequencies, the maximum useful dose of contrast agent may be increased, thereby permitting further lengthening of the useful imaging time window.

This embodiment of the invention is particularly suited to perfusion imaging, for example myocardial perfusion imaging. It will be appreciated that spatial resolution, which may to some extent be compromised by the use of low imaging frequencies, may not be a critical parameter in such imaging.

30 By way of illustration of the lengthened imaging time windows which may be achieved using this embodiment, it has been found that harmonic imaging of a dog heart at 1.5 MHz produced useful results immediately after administration of a contrast agent comprising
35 phosphatidylserine-stabilised perfluorobutane microbubbles.

Contrast agents useful in this embodiment of the invention include gas microbubbles encapsulated by

- 9 -

flexible membranes such that they readily undergo oscillations under the influence of ultrasound energy. They may therefore, for example, comprise amphiphile-stabilised, e.g. phospholipid-stabilised gas
5 microbubbles, for example as hereinbefore described. Again the use of negatively charged phospholipids such as phosphatidylserines, e.g. to stabilise fluorinated gases such as perfluorobutane, may be particularly advantageous.

10 Alternatively the contrast agent microbubbles may be less flexibly encapsulated, e.g. by stabilised protein shells, where the encapsulating material is capable of transiently softening and becoming more elastic under the influence of ultrasound energy,
15 thereby permitting volume oscillation.

It may be advantageous during imaging in accordance with the method of the invention, especially in cardiac imaging, to induce pharmacological stress in the subject. As is well known, such stress may enhance the 20 distinction between normally perfused healthy tissue, e.g. of the myocardium, and tissue regions supplied by stenotic arteries. Thus healthy tissue undergoes vasodilatation and increased blood flow, and may therefore exhibit significantly increased contrast echo.
25 Blood flow in underperfused tissue supplied by a stenotic artery, on the other hand, is substantially unchanged as a result of the capacity for arteriolar vasodilatation already being exhausted by inherent autoregulation seeking to increase the restricted blood
30 flow.

Such pharmacological stress is conveniently induced by administration, e.g. by injection, of a vasodilator, preferably while imaging is being performed during the recirculating phase.

35 Representative examples of vasodilators which may be used include adenosine, dipyridamole, nitroglycerine, isosorbide mononitrate, prazosin, doxazosin, hydralazine, dihydralazine, sodium nitroprusside,

- 10 -

pentoxyphylline, amelodipine, felodipine, isradipine, nifedipine, nimoidipine, verapamil, diltiazem and nitric oxide. Stress-inducing agents such as arbutamine and dobutamine, which have a secondary vasodilatation-inducing effect as a result of their metabolism-increasing effects, may similarly be used. Use of adenosine is particularly preferred since it is an endogenous substance and has a rapid but short-lived vasodilatating effect. This latter property is confirmed by the fact that it has a blood pool half-life of only a few seconds; possible discomfort to patients during vasodilatation is therefore minimised.

Vasodilatation induced by adenosine will be most intense in the heart since the drug will tend to reach more distal tissues in less than pharmacologically active concentrations; it is therefore the vasidilator of choice in echocardiographic applications of this embodiment of the invention.

The following non-limitative Examples serve to illustrate the invention.

- 11 -

Example 1

Cardiac imaging in a dog

5 An ultrasound contrast agent prepared as in Example 2(b) of WO-A-9729783 was injected intravenously into an anaesthetised dog as an intravenous bolus at dose levels corresponding to 1, 9 and 30 times the normal dose for imaging of the first-pass bolus effect, i.e. at doses
10 corresponding to 0.03, 0.27 and 0.9 μ l of gas per kg body weight of the dog. The myocardium was imaged with an ATL HDI-3000 scanner equipped with a P3-5 transducer, operating in harmonic mode with a transmitted frequency of 2.1 MHz and a received frequency of 4.2 MHz. One
15 image was recorded in each end-systole, using ECG gating. The useful imaging time windows for the different doses were respectively found to be 45 seconds, 7 minutes and in excess of 45 minutes.

20 Example 2

Cardiac imaging in a human

An ultrasound contrast agent prepared as in Example 2(b) of WO-A-9729783 is injected intravenously into a patient with a known left anterior descending coronary artery stenosis, as an intravenous bolus of 0.15 μ l of gas per kg body weight of the patient. This corresponds to 5 times the normal dose for imaging of the first-pass
25 bolus effect. The heart is imaged with a Hewlett Packard Sonos 2500 scanner operating in second harmonic mode with a transmitted frequency of 1.8 MHz, with the transducer in the parasternal short axis position. One end-systolic image is recorded every second heartbeat.
30 After 5 minutes, still in the useful imaging time window, an infusion of adenosine is started at a rate of 140 μ g/kg/minute. Some 30 seconds later, an increase in regional contrast echo intensity is seen in that part of
35

- 12 -

the myocardium supplied by normal arterial branches; the area supplied by the stenotic artery does not show such an increase.

5 Example 3

Imaging at lower frequencies

In a similar procedure to that described in Example 1,
10 using the same brand of scanner and settings, imaging
was performed using either a P3-2 transducer
transmitting at 1.8 MHz or a P5-3 transducer
transmitting at 2.1 MHz. The contrast agent was
repeatedly injected at a dose level corresponding to
15 0.03 µl of gas per kg body weight of the dog. Apparent
contrast enhancement of the myocardium was more intense
with the P3-2 transducer, and ultrasound signal
attenuation in the blood-filled left ventricle during
peak bolus passage was observed to be less with this
20 transducer. Additionally, the duration of adequate
contrast effect after the initial phase of ventricular
attenuation was greater using the P3-2 transducer.

- 13 -

Claims:

1. A method of ultrasound imaging which comprises
(i) administering an ultrasound contrast agent
5 comprising stabilised dispersion of gas microbubbles in
an injectable carrier liquid to the vascular system of a
subject in an amount which is physiologically tolerable
and sufficient to generate contrast enhancement within
blood in a recirculating phase following admixture of
10 the agent with the blood pool; and
(ii) generating an ultrasound image of at least a part
of the vascular system of said subject during said
recirculating phase.

15 2. A method as claimed in claim 1 wherein the contrast
agent comprises gas microbubbles stabilised at the gas-
carrier liquid interfaces by monolayers of amphiphilic
material.

20 3. A method as claimed in claim 2 wherein said
amphiphilic material comprises at least one
phospholipid.

25 4. A method as claimed in claim 3 wherein said
amphiphilic material consists essentially of
phospholipid predominantly comprising molecules which
individually have an overall net charge.

30 5. A method as claimed in claim 4 wherein
substantially all of the phospholipid consists of
molecules which individually have an overall net
negative charge.

35 6. A method as claimed in claim 5 wherein one or more
phosphatidylserines constitute at least 70% of the
phospholipid.

7. A method as claimed in any of the preceding claims

- 14 -

wherein the gas microbubbles comprise sulphur hexafluoride or a perfluorinated low molecular weight hydrocarbon.

5 8. A method as claimed in claim 7 wherein the perfluorinated low molecular weight hydrocarbon is perfluorobutane.

10 9. A method as claimed in any of the preceding claims wherein an imaging frequency of 2 MHz or less is transmitted.

15 10. A method as claimed in any of claims 1 to 8 wherein in step (ii) the ultrasound image is generated using a non-linear imaging technique.

11. A method as claimed in claim 10 wherein the ultrasound image is generated by second harmonic imaging.

20 12. A method as claimed in claim 10 or claim 11 wherein the contrast agent comprises gas microbubbles stabilised at the gas-carrier liquid interfaces by monolayers consisting essentially of phospholipid which predominantly comprises molecules which individually have an overall net charge, and said contrast agent is administered in a dose corresponding to 2-10 µg of phospholipid per kg body weight of the subject.

30 13. A method as claimed in any of claims 10 to 12 wherein in step (ii) the ultrasound image is generated using a transmit frequency below the mean resonance frequency of the gas microbubbles.

35 14. A method as claimed in any of claims 10 to 12 wherein in step (ii) the ultrasound image is generated using a transmit frequency of 2 MHz or less.

- 15 -

15. A method as claimed in claim 14 wherein the transmit frequency is about 1.5 MHz.

16. A method as claimed in any of the preceding claims
5 wherein pharmacological stress is induced in the subject during the ultrasound imaging.

17. A method as claimed in claim 16 wherein
pharmacological stress is induced by administration of a
10 vasodilator to the subject.

18. A method as claimed in claim 17 wherein said
vasodilator is adenosine.

15 19. A method as claimed in claim 17 or claim 18 wherein
the vasodilator is injected into the subject during
ultrasound imaging in the recirculating phase.

20 20. Use of stabilised gas microbubbles in the
manufacture of an ultrasound contrast agent for
application in a method as defined in any of the
preceding claims.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 98/02481

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K49/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|--|-----------------------|
| P, X | WO 97 44067 A (ANDARIS LTD ; JOHNSON RICHARD ALAN (GB); WOUW PAULUS ANTONIUS V D () 27 November 1997 see page 27, line 19 - page 28, line 9; claims 1-4 --- | 1 |
| P, X | WO 97 29783 A (MARDSEN JOHN CHRISTOPHER ; BRAENDEN JORUN (NO); DUGSTAD HARALD (NO)) 21 August 1997 cited in the application see page 12, line 10-14; claims 1-79; examples 1-3 --- | 1-15 |
| P, X | WO 98 17324 A (MARDSEN JOHN CHRISTOPHER ; ERIKSEN MORTEN (NO); OESTENSEN JONNY (NO)) 30 April 1998 see claims 22-29 --- | 16-19 -/- |

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

9 December 1998

29/12/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Veronese, A

INTERNATIONAL SEARCH REPORT

Inte: National Application No

PCT/GB 98/02481

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|--|-----------------------|
| X | WO 96 26746 A (ALLIANCE PHARMA) 6 September 1996 | 1-15 |
| Y | see page 5, line 18-26 see page 6, line 5-19; claims; examples 1-10 --- | 1-15 |
| Y | WO 94 08627 A (DELTA BIOTECHNOLOGY LTD ; SUTTON ANDREW DEREK (GB); JOHNSON RICHARD) 28 April 1994 see page 17, line 30 - page 18, line 24 see page 20, line 16-21; claim 11 --- | 1-15 |
| Y | EP 0 324 938 A (MOLECULAR BIOSYSTEMS INC) 26 July 1989 see page 3, line 4-16; claim 1 --- | 1-15 |
| Y | MALCOM ROWLAND AND AL.: "Clinical Pharmacokinetics: concepts and applications" , LEA AND FEBIGER , PHILADELPHIA XP002087081 * See figure 12-9, pag. 166 * see page 155 - page 172 --- | 1-15 |
| Y | WO 94 09829 A (SINT SA) 11 May 1994 see the whole document --- | 1-15 |
| X | PORTER T.R.: "Detection of myocardial perfusion in multiple echocardiographic windows with one intravenous injection of microbubbles using transient response second harmonic imaging" JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 29, no. 4, 15 March 1997, pages 791-799, XP002087079 see the whole document ----- | 13-19 |
| X | PORTER T.R. ET AL.: "Detection of regional perfusion abnormalities during adenosine stress echocardiography with intravenous perfluorocarbon-exposed sonicated dextrose albumin" AMERICAN HEART JOURNAL, vol. 132, 1996, pages 41-47, XP002087080 see the whole document ----- | 16-19 |

INTERNATIONAL SEARCH REPORT

II. International application No.

PCT/GB 98/02481

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 1-19 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/02481

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|--|---|------------------|--|--|
| WO 9744067 | A | 27-11-1997 | AU 2909597 A | 09-12-1997 |
| WO 9729783 | A | 21-08-1997 | AU 1805197 A AU 1884797 A EP 0881915 A WO 9729782 A NO 983420 A | 02-09-1997 02-09-1997 09-12-1998 21-08-1997 24-07-1998 |
| WO 9817324 | A | 30-04-1998 | AU 4714797 A | 15-05-1998 |
| WO 9626746 | A | 06-09-1996 | US 5798091 A AU 4922196 A CA 2212113 A CN 1182373 A EP 0812214 A FI 973496 A NO 973489 A PL 321952 A | 25-08-1998 18-09-1996 06-09-1996 20-05-1998 17-12-1997 26-08-1997 27-08-1997 05-01-1998 |
| WO 9408627 | A | 28-04-1994 | EP 0663840 A GB 2286122 A,B GB 2302649 A,B GB 2302650 A,B JP 8505366 T | 26-07-1995 09-08-1995 29-01-1997 29-01-1997 11-06-1996 |
| EP 0324938 | A | 26-07-1989 | US 4844882 A CA 1325590 A CN 1035774 A,B DE 3885730 D DE 3885730 T DK 721688 A FI 886016 A,B, IE 61591 B JP 1203337 A JP 6062445 B KR 9605709 B NO 176826 B | 04-07-1989 28-12-1993 27-09-1989 23-12-1993 10-03-1994 30-06-1989 30-06-1989 16-11-1994 16-08-1989 17-08-1994 01-05-1996 27-02-1995 |
| WO 9409829 | A | 11-05-1994 | AT 146972 T AU 2618197 A AU 681812 B AU 3431795 A AU 666238 B AU 5336294 A CA 2125027 A CN 1088456 A DE 69307124 D DE 69307124 T DK 619743 T EP 0619743 A ES 2097548 T FI 943167 A GR 3022826 T HU 74561 A IL 107453 A JP 7503254 T NO 942476 A NZ 257115 A | 15-01-1997 18-12-1997 04-09-1997 04-01-1996 01-02-1996 24-05-1994 11-05-1994 29-06-1994 13-02-1997 17-07-1997 20-01-1997 19-10-1994 01-04-1997 01-07-1994 30-06-1997 28-01-1997 04-01-1998 06-04-1995 30-06-1994 24-06-1997 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte onal Application No

PCT/GB 98/02481

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|--|------------------|---|--|
| WO 9409829 A | | NZ 280615 A US 5445813 A US 5597549 A US 5686060 A ZA 9308117 A | 24-02-1997 29-08-1995 28-01-1997 11-11-1997 23-06-1994 |